Skip to main content

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

         TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that CEO Thomas Jensen has been invited to participate as a speaker at Precision Medicine Forum Europe 2026, taking place May 11–12, 2026, in Stockholm, Sweden. Presentation Details: Event: Precision Medicine Forum Europe 2026Presentation Title: Dual Inhibition of PARP and WNT: A Novel Drug-Biomarker Combination in Clinical TrialsTrack: OncologyDate: Monday, May 11, 2026Time: 10:20–10:40 CEST Mr. Jensen will discuss stenoparib’s dual mechanism of action and Allarity’s predictive biomarker, the Stenoparib DRP®, based on a 414-mRNA gene expression signature, which...

Continue reading

Gencor Releases Second Quarter Fiscal 2026 Results

ORLANDO, Fla., May 08, 2026 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenue for the quarter ended March 31, 2026 was $33,799,000 compared with $38,204,000 net revenue for the quarter ended March 31, 2025. The decrease in net revenue was primarily due to lower contract equipment revenues recognized over time and associated freight revenue, which resulted from the timing of orders and shipments. As a percentage of net revenue, gross profit margins increased 200 basis points to 31.7% in the quarter ended March 31, 2026, compared to 29.7% in the quarter ended March 31, 2025. Product engineering and development expenses decreased $52,000 to $629,000 for the quarter ended March 31, 2026, as compared to $681,000 for the quarter ended March 31, 2025 primarily due to...

Continue reading

Alamar Biosciences Reports First Quarter 2026 Financial Results

FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) — Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended March 31, 2026. Recent HighlightsGenerated $26.0 million of total revenue for the first quarter of 2026, an increase of 99% as compared to the corresponding period of 2025. Launched two new products, NULISAseq™ Neuro 220 Panel and NULISAqpcr™ AD 5-plex Assay, furthering our leadership in neurodegenerative disease research. Raised approximately $220 million in gross proceeds from our initial public offering in April 2026.“We began 2026 with a record quarter, nearly doubling revenue year over year as our NULISA platform gained rapid global traction among leading academic research...

Continue reading

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

– Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination – – Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and potentially derisks path forward in HER2-positive breast cancer – – Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer is on track for topline data mid-2027 – – Phase 1 trial evaluating ALX2004 continues to enroll well, on track for safety data in 2H 2026 – – ALX strengthens leadership team with the appointment of Jeff Knight as Chief Development and...

Continue reading

Antelope Enterprise Holdings Limited Announces $190,000 in Realized Gains from its “Genius Plan” and Authorizes an $95,000 Share Repurchase Program, Validating its Sustainable Capital Recycling Framework

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) — Antelope Enterprise Holdings Limited (NASDAQ: AEHL, or the “Company”), today announced significant milestones in its structured digital asset allocation strategy, the “Genius Plan”. Initially launched in February 2026 as a dynamic framework to manage Bitcoin (BTC) treasury reserves, the Genius Plan has successfully transitioned into its execution validation phase, generating $190,000 in realized investment gains, as of this announcement. In direct alignment with the predefined capital recycling and return distribution mechanisms established at the plan’s inception, the Company’s Board of Directors has authorized a share repurchase program. The Company will utilize 50% of these newly realized gains – totaling $95,000 – to repurchase issued and outstanding ordinary shares in the open...

Continue reading

Myseum.AI to Present at 16th Annual LD Micro Invitational Conference; Picture Party Named Official Private Social Media Platform

NEW BRUNSWICK, N.J., May 08, 2026 (GLOBE NEWSWIRE) — Myseum.AI, Inc. (Nasdaq: MYSE) (“Myseum.AI” or the “Company”) a privacy-first AI and social media technology company, today announced that Chief Executive Officer Darin Myman will present at the 16th Annual LD Micro Invitational conference taking place May 17–19, 2026, in Los Angeles. Myseum.AI’s flagship next-generation instant social networking experience, Picture Party, is featured as the official private social media platform for the conference. Myman’s presentation is scheduled for Tuesday, May 19, 2026, at 11:00 a.m. PT. and will be webcast live. Management will be available for private on-on-one meetings with investors on May 18th and 19th. The presentation will focus on Picture Party, a next-gen patented instant social networking platform that enables...

Continue reading

Costamare Bulkers Holdings Limited Sets the Date for Its First Quarter 2026 Results Release, Conference Call and Webcast

Earnings Release: Wednesday, May 13, 2026, Before Market OpensConference Call and Webcast: Wednesday, May 13, 2026, at 8:30 a.m. ET MONACO, May 08, 2026 (GLOBE NEWSWIRE) — Costamare Bulkers Holdings Limited (NYSE:CMDB) (“Costamare Bulkers” or the “Company”), announced today that it will release its results for the first quarter ended March 31, 2026 before the market opens in New York on May 13, 2026. Conference Call Details: On Wednesday, May 13, 2026 at 8:30 a.m. ET, Costamare Bulkers’ management team will hold a conference call to discuss the financial results. Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 1-844-887-9405 (from the US) or +1-412-317-9258 (from outside the US). Please quote “Costamare Bulkers”. A replay of the conference call will be available...

Continue reading

Micropolis Robotics Emerges as the Leading UAE Technology Success Story at Make it in the Emirates 2026

ABU DHABI, United Arab Emirates, May 08, 2026 (GLOBE NEWSWIRE) — Micropolis AI Robotics (NYSE: MCRP) (“Micropolis” or the “Company”), a leading UAE-based developer of autonomous mobile robots and AI-enabled systems, concluded Make it in the Emirates 2026 with strong national recognition, major commercial momentum, and one of the event’s defining advanced technology showcases.The Company was featured during the opening ceremony as the event’s standout UAE success story in the technology sector, with the Company’s growth journey and technological achievements highlighted before senior UAE leadership, including His Highness Sheikh Mansour bin Zayed Al Nahyan, Vice President, Deputy Prime Minister and Chairman of the Presidential Court, and His Excellency Dr. Sultan Ahmed Al Jaber, Minister of Industry and Advanced Technology, Managing...

Continue reading

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) —  InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share. The aggregate gross proceeds from the offering were $150 million, before deducting the underwriting discount and offering expenses. The Company intends to use the net proceeds from the offering to advance its pipeline activities and for working capital and general corporate purposes. The financing included participation from new and existing investors, including TCGX, a large healthcare-dedicated fund, Farallon Capital Management, Sirenia Capital Management LP, Columbia Threadneedle...

Continue reading

3 E Network Launches Proactive Financing Strategy to Accelerate Semiconductor Blueprint, Officially Establishing Chip Business Unit

HONG KONG, May 08, 2026 (GLOBE NEWSWIRE) — 3 E Network Technology Group Limited (Nasdaq: MASK) (the “Company” or “3 E Network”), a business-to-business (“B2B”) information technology (“IT”) business solutions provider committed to becoming a next-generation artificial intelligence (“AI”) infrastructure solutions provider, today announced the advancement of a proactive capital-raising strategy designed to robustly fund its recently unveiled semiconductor and compute infrastructure blueprint. The Company has secured a $1.3 million convertible note agreement with an institutional investor. This capital, along with ongoing financing initiatives, will directly fuel the “Vertically Integrated Ecosystem” strategy led by Vice President Mr. Siyang Hu, accelerating the Company’s evolution from a system integrator to a developer of proprietary...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.